Continuing Medical Education
Anticoagulation: Where have we come from and where are we going? The evidence for and against novel anticoagulants
Warfarin, one of the vitamin K antagonists, has been used since 1940, when it was first approved for the treatment of venous thromboembolism. It is currently the most commonly used anticoagulant, although alternative drugs are available, such as aspirin, clopidogrel and dipyridamol, which have been studied in a number of scenarios. The newest agents available to clinicians are the broad group of novel anticoagulants, such as direct thrombin and direct factor Xa inhibitors, including molecules such as dabigatran, rivaroxaban, apixaban and edoxaban.
Greg Symons, Division of Pulmonology, Department of Medicine, Groote Schuur Hospital, Cape Town, South Africa
Full TextPDF (719KB)
Cite this article
Date published: 2014-01-12
Full text views: 1329